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ABSTRACT
Background: First-generation drug-eluting stents
(DES) have become the most widely used devices
worldwide for management of coronary artery disease.
As remote follow-up data were becoming available,
concerns emerged in regard to their long-term safety.
Second-generation DES were designed to overcome
safety issues, but the results of randomised clinical
trials remain conflicting.
Methods: We compared the safety and efficacy of
first-generation versus second-generation Food and
Drug Administration approved DES; the following
devices were included: first-generation sirolimus-
eluting stent (SES) and paclitaxel-eluting stents (PES);
second-generation everolimus-eluting stent (EES),
zotarolimus-eluting stent Endeavor and ZES-Resolute
(ZES-R). Prespecified safety end points comprised ≤1
and >1 year: overall and cardiac mortality, myocardial
infarction (MI), definite/definite or probable ST; efficacy
end points were target lesion revascularisation and
target vessel revascularisation. Composite end points
were analysed as well.
Results: 33 randomised controlled trials involving
31 379 patients with stable coronary artery disease or
acute coronary syndrome undergoing DES implantation
were retrieved. No differences in mortality among
devices were found. In the overall class comparison,
second-generation DES were associated with a 22%
reduction of odds of MI at short-term OR 0.77 (95%
CI 0.68 to 0.89) p=0.0002; EES reduced the odds of
definite-probable ST compared with PES: OR 0.33
(95% CI 0.15 to 0.73) p=0.006; First-generation SES
along with second-generation EES and ZES-R showed
similar efficacy in decreasing the odds of repeat
revascularisation.
Conclusions: Second-generation EES and ZES-R offer
similar levels of efficacy compared with first-generation
SES, but are more effective than PES; however, only
second-generation EES significantly reduced the
incidence of MI and ST, and therefore should be
perceived as the safest DES to date.
INTRODUCTION
Over the past 10 years, ﬁrst-generation drug-
eluting stents (DES), especially sirolimus-
eluting stent (SES) and paclitaxel-eluting
stents (PES), have become the most widely
used devices worldwide for management of
coronary artery disease. However, despite
their clear superiority in preventing resten-
osis and the need for repeat revascularisation
due to eluted antiproliferative drugs is cer-
tainly proven,1 as remote follow-up data were
becoming available, concerns emerged in
regard to their long-term safety, strictly late
and very late thrombotic events, in turn asso-
ciated with a high rate of death and
KEY MESSAGES
What is already known about this subject?
▸ Second generation DES are similarly effective as
first generation DES.
What does this study add?
▸ Everolimus eluting stent was found to signifi-
cantly reduce the odds of myocardial infarction
and stent thrombosis.
How might this impact on clinical practice?
▸ No differences in mortality was found between
these devices.
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Table 1 Characteristics of included studies
Study Journal Year
Number
of
patients
First
generation
Second
generation
Short-term
follow-up
(≤12 months)
Long-term
follow-up
(>12 months)
Primary
end point
MACE/TVF
definition
Clinical
setting
Minimal DAPT
duration (ADP
receptor/
P2Y12 inhibitor)
Protocol
defined
follow-up
angiography
APPENDIX-AMI13 14 PLoS ONE 2013 977 SES Cypher EES Xience V 12 months* 24 months MACE Cardiac
mortality, MI,
TVR
Stable/
ACS
12 months No
BASKET-PROVE15 NEJM 2010 1549 SES Cypher EES Xience V n.r. 24 months MACE Mortality, MI,
TVR
Stable/
ACS
12 months No
CATOS16 Circulation Journal 2012 160 SES Cypher ZES
Endeavor
12 months n.r. In-segment binary
restenosis rate at
9 months
angiographic
follow-up
Cardiac
mortality, MI,
TVR
CTO 12 months Yes
CIBELES17 Circulation
Cardiovascular
Interventions
2013 207 SES Cypher EES Xience V 12 months n.r. In-stent late loss at
9 months
angiographic
follow-up
Mortality, MI,
TVR
TCO 12 months Yes
COMPARE18–20 Lancet
JACC
2010
2011
1800 PES Taxus
Liberte
EES Xience V 12 months 24, 36 months MACE Mortality, MI,
TVR
Stable/
ACS
12 months No
ENDEAVOR III21 22 JACC
JACC
Cardiovascular
Interventions
2006
2011
436 SES Cypher ZES
Endeavor
9 months 60 months In-segment late
lumen loss at
8 months
angiographic
follow-up
Mortality, MI,
TLR
Stable/
ACS
3 months Yes
ENDEAVOR IV23 24 JACC
JACC
Cardiovascular
Interventions
2010
2013
1548 PES Taxus
Express
ZES
Endeavor
12 months 60 months TVF at 9 months Mortality, MI,
TLR
Stable/
ACS
6 months Yes
ESSENCE-Diabetes25 Circulation 2011 300 SES Cypher EES Xience V 12 months n.r. In-segment late
lumen loss at
8 months
angiographic
follow-up
Mortality, MI,
TLR
Stable/
ACS
12 months Yes
EXCELLENT26 JACC 2011 1428 SES Cypher EES Xience V
or Promus
12 months n.r. In-segment late
lumen loss at
9 months
angiographic
follow-up
Cardiac
mortality, MI,
TLR
Stable/
ACS
6 months Yes
EXECUTIVE27 JACC
Cardiovascular
Interventions
2013 200 PES Taxus
Liberte
EES Xience V 12 months n.r. In-segment late
lumen loss at
9 months
angiographic
follow-up
Mortality, MI,
TVR
Stable/
ACS
6 months Yes
ISAR-TEST-228 29 EHJ
JACC
2009
2010
674 SES Cypher ZES
Endeavor
12 months 24 months binary angiographic
restenosis at 6–
8-month follow-up
angiography
Mortality, MI,
TLR
Stable/
ACS
12 months Yes
KOMER30 EuroIntervention 2011 611 SES Cypher
and PES Taxus
Express
ZES
Endeavor
12 months 18 months MACE Cardiac
mortality, MI,
TLR
STEMI 12 months Yes
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Table 1 Continued
Study Journal Year
Number
of
patients
First
generation
Second
generation
Short-term
follow-up
(≤12 months)
Long-term
follow-up
(>12 months)
Primary
end point
MACE/TVF
definition
Clinical
setting
Minimal DAPT
duration (ADP
receptor/
P2Y12 inhibitor)
Protocol
defined
follow-up
angiography
LONG-DES III31 JACC 2011 450 SES Cypher EES Xience V
or Promus
12 months n.r. In-segment late
lumen loss at
9 months
angiographic
follow-up
Mortality, MI,
TVR
Stable/
ACS
12 months Yes
LONG-DES IV32 Circulation
Cardiovascular
Interventions
2012 500 SES Cypher ZES Resolute 12 months n.r. In-segment late
lumen loss at
9 months
angiographic
follow-up
Mortality, MI,
TVR
Stable/
ACS
12 months Yes
Naples-Diabetes33 Circulation
Cardiovascular
Interventions
2011 226 SES Cypher
and PES Taxus
Liberte
ZES
Endeavor
In-hospital;
12 months
36 months MACE Mortality, MI,
TVR
Stable/
ACS
6 months No
PRISON III34 EuroIntervention 2013 304 SES Cypher ZES Resolute
or ZES
Endeavor
12 months n.r. In-segment late
lumen loss at
8 months
angiographic
follow-up
Mortality, MI,
TLR
TCO 12 months Yes
R-CHINA RCT35 JACC
Cardiovascular
Interventions
2013 400 PES Taxus
Liberte
ZES Resolute 12 months n.r. In-stent late lumen
loss at 9 months
angiographic
follow-up
Mortality, MI,
TLR
Stable/
ACS
6 months Yes
RESET36 Circulation 2012 3197 SES Cypher EES Xience V 12 months n.r. TLR at 12 months;
composite of
all-cause death and
MI at 36 months
Cardiac
mortality, MI,
TLR
Stable/
ACS
3 months No
Sakakibara et al37 Circulation Journal 2012 100 SES Cypher EES Xience V 12 months n.r. binary angiographic
restenosis at 8 month
follow-up
angiography
Mortality, MI,
TLR
Stable 12 months Yes
Sawada et al38 International
Journal of
Cardiology
2012 35 SES Cypher EES Xience V
or Promus
7 months n.r. Neointimal thickness
and ST
n.a. STEMI 7 months Yes
SEA-SIDE39 JACC
Cardiovascular
Interventions
2011 150 SES Cypher EES Xience V n.r. 18 months Occurrence of any
trouble in the
side-branch (SB)
management
Mortality, MI,
TVR
Stable/
ACS
12 months No
SEZE40 Chinese Medical
Journal
2012 122 SES Cypher ZES
Endeavor
12 months n.r. In-stent late lumen
loss at 9 months
angiographic
follow-up
Cardiac
mortality, MI,
TVR
STEMI 12 months Yes
Song et al41 JACC 2012 1114 SES Cypher EES Xience V 12 months n.r. In-segment late
lumen loss at
9 months
angiographic
follow-up
Mortality, MI,
TVR
Stable/
ACS
6 months Yes
Continued
N
avarese
E
P
,
K
ow
alew
ski
M
,
K
an
d
zari
D
,
et
al.
O
p
en
H
eart
2
0
1
4
;1
:e0
0
0
0
6
4
.
d
o
i:1
0
.1
1
3
6
/o
p
en
h
rt-2
0
1
4-0
0
0
0
6
4
3
M
e
ta
-a
n
a
ly
s
is
group.bmj.com
 o
n
 February 27, 2015 - Published by 
http://openheart.bmj.com/
D
ow
nloaded from
 
Table 1 Continued
Study Journal Year
Number
of
patients
First
generation
Second
generation
Short-term
follow-up
(≤12 months)
Long-term
follow-up
(>12 months)
Primary
end point
MACE/TVF
definition
Clinical
setting
Minimal DAPT
duration (ADP
receptor/
P2Y12 inhibitor)
Protocol
defined
follow-up
angiography
SORT OUT III42 43 Lancet
JACC
Cardiovascular
Interventions
2010
2013
2332 SES Cypher ZES
Endeavor
9 months 36 months MACE Cardiac
mortality, MI,
TVR
Stable/
ACS
12 months No
SORT OUT IV44 45 Circulation
JACC
2012
2012
2774 SES Cypher EES Xience V
or Promus
9 months 24, 36
[ref-tctmd]
months
MACE Cardiac
mortality, MI,
TVR, def. ST
Stable/
ACS
12 months No
SPIRIT II46 47 EuroIntervention
EuroIntervention
2007
2012
300 PES Taxus
Liberte or PES
Taxus Express
EES Xience V 12 months 60 months In-stent late lumen
loss at 6 months
angiographic
follow-up
Cardiac
mortality, MI,
TLR
Stable/
ACS
12 months Yes
SPIRIT III48 49 JAMA
The American
Journal of
Cardiology
2008
2011
1001 PES Taxus
Express
EES Xience V 12 months 36, 60 [ref
stone ppt]
months
In-stent late lumen
loss at 8 months
angiographic
follow-up
Cardiac
mortality, MI,
TLR
Stable/
ACS
6 months Yes
SPIRIT IV50 51 NEJM
JACC
2010
2011
3687 PES Taxus
Express
EES Xience V 12 months 24 months Composite of cardiac
death, target vessel
MI and TLR
Cardiac
mortality, MI,
TLR
Stable/
ACS
12 months No
SPIRIT V Diabetic
Study52
American Heart
Journal
2012 324 PES Taxus
Liberte
EES Xience V 12 months n.r. In-stent late lumen
loss at 9 months
angiographic
follow-up
Mortality, MI,
TVR
Stable/
ACS
6 months Yes
Wang et al53 JACC abstracts 2011 875 SES Cypher ZES
Endeavor
6 months n.r. MACE Cardiac
mortality, MI,
TLR
STEMI n.r. No
XAMI54 JACC 2012 625 SES Cypher EES Xience V 12 months n.r. MACE Cardiac
mortality, MI,
TVR
STEMI 12 months No
ZEST55 JACC 2010 2645 SES Cypher or
PES Taxus
Liberte
ZES
Endeavor
12 months n.r. MACE Mortality, MI,
TVR
Stable/
ACS
12 months Yes
ZEST-AMI56 57 The American
Journal of
Cardiology
2009 328 SES Cypher or
PES Taxus
Liberte
ZES
Endeavor
12 months n.r. MACE Mortality, MI,
TVR
STEMI 12 months Yes
ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; EES, everolimus-eluting stent; MACE, major adverse cardiovascular events; MI, myocardial infarction; PES, paclitaxel-eluting
stent; SES, sirolimus-eluting stent; STEMI, ST elevation myocardial infarction; TLR, target lesion revascularisation; TVR, target vessel revascularisation; ZES, zotarolimus-eluting stent.
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myocardial infarction (MI).2 3 Such events have been
attributed to the incomplete re-endothelialisation
caused by the drug-induced inhibition of endothelial
cell proliferation, stent malapposition, accelerated
neoatherosclerosis and, importantly, polymer-induced
prolonged vessel wall inﬂammation.4 Second-generation
DES were designed to overcome safety issues in the long
term, employing new biocompatible polymer coatings,
less toxic antiproliferative drugs and eventually
state-of-the-art thin strut Co-Cr metal alloys, and exten-
sively tested in randomised clinical trials (RCTs). The
everolimus-eluting stent (EES) has been found to be
safer than ﬁrst-generation and biodegradable DES;5 on
the other hand, zotarolimus-eluting stent (ZES) was
inferior to SES in terms of major adverse cardiac events
(MACE) and superior to PES in terms of MI in inde-
pendent recent meta-analyses of RCTs.6 7
Driven by conﬂicting evidence on ﬁrst-generation
versus second-generation DES performance in regard to
efﬁcacy and safety along with another recent
meta-analysis8 showing signiﬁcant outcomes in one com-
parison only (ST rates reduction with second-generation
EES vs ﬁrst-generation PES, we performed a comprehen-
sive and updated meta-analysis of all relevant DES data
published to date comparing ﬁrst-generation and
second-generation DES in clinical practice.
METHODS
We compared the safety and efﬁcacy of ﬁrst-generation vs
second-generation Food and Drug Administration (FDA)
approved DES; the following devices were included: ﬁrst-
generation SES and PES, 2) second-generation EES,
ZES-Endeavor ( ZES-E) and ZES-Resolute (ZES-R).
Established methods were used in adherence to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement for reporting systematic
reviews and meta-analyses in healthcare interventions.9
Relevant RCTs were searched until September 2013
through MEDLINE, the Cochrane Central Register of
Controlled Trials (CENTRAL), Google Scholar and
EMBASE databases and through http://www.tctmd.com,
http://www.clinicaltrials.gov, http://www.clinicaltrialresults.
org and http://www.cardiosource.com websites; documents
accessible through the FDA website were scrutinised as well.
The following keywords were used: “randomized trials”,
“drug-eluting stent”, “durable polymer stent”, “sirolimus
stent”, “paclitaxel stent”, “everolimus stent”, “zotarolimus
stent”, “Endeavor zotarolimus-stent”, “Resolute
zotarolimus-stent”. No language, date or publication status
restrictions were imposed. For each RCT, the most updated
or most inclusive data were used.
Citations were screened at the title/abstract level and
retrieved as full reports. Inclusion criteria were: (1)
Figure 1 Flow diagram of the review process according to the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement.
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human studies; (2) RCTs; (3) studies comparing safety
AND/OR efﬁcacy of ﬁrst-generation versus second-
generation durable polymer DES; (4) additional data
from retrieved studies available at a longer follow-up.
Exclusion criteria were: (1) non-RCTs; (2) a substudy of
RCTs; (3) a bare metal stent (BMS), biodegradable/
bioabsorbable stent or polymer-free stent as the control
group, (4) RCTs comparing DES within their class.
Internal validity was appraised according to the proper
allocation sequence/concealment, patient blinding,
investigator blinding and complete outcome data/full
reporting.
Prespeciﬁed safety end points comprised ≤1 year:
overall and cardiac mortality, MI and deﬁnite/deﬁnite
or probable ST according to the deﬁnition criteria of
the Academic Research Consortium (ARC).10 Efﬁcacy
Figure 2 Analysis of all-cause mortality at short-term (A) and long-term (B) follow-up. ORs and 95% CIs. Size of squares is
proportional to the statistical weight of each trial.
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end points were target lesion revascularisation (TLR)
and target vessel revascularisation (TVR). We also ana-
lysed the composite end point of MACE to appreciate
the cumulative effect of combining non-frequent safety
and efﬁcacy adverse events; the MACE deﬁnition of each
individual study was accepted, although it varied across
studies (table 1). To account for over time changes in
both the DES properties and eluted drug release
kinetics, analyses of each clinical outcome were repeated
at longest available, beyond 1 year follow-up.
Statistical analysis
Data were analysed according to the intention-to-treat prin-
ciple. ORs and 95% CIs were used as summary statistics.
Heterogeneity was assessed by the Cochran Q test.
Statistical heterogeneity was summarised by the I2 statistic,
which quantiﬁes the percentage of variation in study results
that is due to heterogeneity rather than chance.11 Pooled
ORs were calculated using a ﬁxed effect model with the
Mantel-Haenszel method. The random effects model was
applied in case of signiﬁcant heterogeneity and/or moder-
ate or signiﬁcant inconsistency (heterogeneity >50%;
inconsistency p≤0.05) across studies.12 Results were consid-
ered statistically signiﬁcant at two-sided p≤0.05. All pooling
analyses were conducted using Review Manager 5.1
(Cochrane Collaboration, Copenhagen, Denmark).
RESULTS
Studies and patient population
The PRISMA ﬂow diagram of the studies selection is pre-
sented in ﬁgure 1. The full electronic MEDLINE database
search process along with inclusion/exclusion criteria and
risk of bias analysis of included studies is shown in the
online supplementary material. Thirty-three13–57 trials
comprising a total of 31 379 patients met the inclusion cri-
teria and entered the analysis. Information on stent com-
parators, clinical setting, minimal DAPT duration and
primary end points is delineated in table 1. Most trials
enrolled high-risk patients with stable coronary artery
disease and acute coronary syndrome presentations, with
six trials restricting their inclusion criteria to STEMI
patients only30 38 40 53 54 56; clopidogrel was administered
across all studies; the composite end point of MACE was
similar throughout the studies and included cardiac
death, MI and repeat revascularisation; detailed deﬁni-
tions are listed in table 1. Funnel plots did not reveal publi-
cation bias or small study effect and are included in the
online supplementary material (see online supplementary
ﬁgure S1A, B).
Mortality, cardiac death
Twenty-nine studies contributed to the analysis of
≤1 year mortality. Second-generation DES were asso-
ciated with results that did not differ signiﬁcantly from
Figure 2 Continued
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those of the ﬁrst-generation in either comparison group:
OR 0.99 (95% CI 0.81 to 1.20) p=0.90. Results in the
long term (13 studies included) were consistent with the
short-term analysis: OR 0.94 (95% CI 0.77 to 1.16)
p=0.58 (ﬁgure 2A). A non-signiﬁcant trend favouring
EES was shown in comparison with PES in the long
term: OR 0.68 (95% CI 0.43 to 1.09) p=0.06 (ﬁgure 2B).
The cardiac mortality analysis did not diverge from
the ﬁndings from all-cause death calculations with OR
1.03 (95% CI 0.81 to 1.31) p=0.79 and OR 1.02 (95% CI
0.79 to 1.31) p=0.89, for short-term and long-term
follow-up, respectively, for overall ﬁrst-generation versus
second-generation stents comparison (see online supple-
mentary ﬁgure S2A,B).
Figure 3 Analysis of MI at short-term (A) and long- term (B) follow-up. ORs and 95% CIs. Size of squares is proportional to the
statistical weight of each trial. MI, myocardial infarction.
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Myocardial infarction
Thirty-one studies were included in the MI analysis in
the short term. EES signiﬁcantly reduced the odds of MI
compared with PES: OR 0.54 (95% CI 0.41 to 0.72)
p<0.0001 (ﬁgure 3A). In the overall class comparison,
second-generation DES were associated with a 23%
reduction of odds of MI OR 0.77 (95% CI 0.68 to 0.89)
p=0.0002 in the short term. A signiﬁcant class effect
favouring second-generation DES was sustained in the
long-term analysis: OR 0.75 (95% CI 0.56 to 1.00)
p=0.05, with the odds of MI halved in comparison with
EES versus PES: OR 0.56 (95% CI 0.44 to 0.72) p<0.001
(ﬁgure 3B).
Stent thrombosis
For the analysis of deﬁnite ST, 26 studies were included.
In the short term, EES was associated with signiﬁcant
reduction of odds of ST compared with PES and SES:
OR 0.34 (95% CI 0.18 to 0.62) p=0.0005 and OR 0.43
(95% CI 0.22 to 0.84) p=0.01, respectively (ﬁgure 4A).
Second-generation ZES-E increased the odds of ST by
122% compared with ﬁrst-generation SES: OR 2.22
(95% CI 1.14 to 4.31) p=0.02. Results in the long term
conﬁrmed short follow-up ﬁndings; EES was associated
with a more pronounced and signiﬁcant reduction of
odds of ST over time as compared with PES and SES:
OR 0.26 (95% CI 0.14 to 0.49) p<0.0001 and OR 0.30
(95% CI 0.11 to 0.78) p=0.01, respectively (ﬁgure 4B).
Analysis of deﬁnite-probable ST reﬂected the direction
of the deﬁnite ST estimates. EES reduced the odds of
deﬁnite-probable ST compared with PES and SES: OR
0.33 (95% CI 0.15 to 0.73) p=0.006 and OR 0.61 (95% CI
0.37 to 1.01) p=0.05 (see online supplementary ﬁgure
3A). Also, at long-term follow-up, a signiﬁcant reduction
of deﬁnite-probable ST odds was observed with EES
versus PES (OR 0.32 (95% CI 0.17 to 0.59) p=0.0002)
and versus SES (OR 0.50 (95% CI 0.28 to 0.88) p=0.02;
see online supplementary ﬁgure 3B). The overall class
comparison of deﬁnite-probable ST favoured second-
generation DES over SES at both short-term (OR 0.67
(95% CI 0.47 to 0.94) p=0.02) and long-term (OR 0.54
(95% CI 0.37 to 0.80) p=0.002) follow-up.
Repeat revascularisation TLR/TVR
Twenty-nine studies reported TLR incidence at short-
term follow-up. First-generation SES along with second-
generation EES and ZES-R showed a similar degree of
efﬁcacy in decreasing the odds of TLR. EES reduced the
odds of TLR by 43% compared with PES (OR 0.57
(95% CI 0.36 to 0.91) p=0.02) and ZES-E markedly
increased the odds in comparison to SES (OR 2.61
(95% CI 1.97 to 3.46) p<0.00001; ﬁgure 5A), with direc-
tion and signiﬁcance of the estimates being sustained
Figure 3 Continued
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over long-term follow-up (12 studies; EES vs PES: OR
0.57 (95% CI 0.46 to 0.72) p<0.00001; and ZES-E vs SES:
OR 1.85 (95% CI 1.18 to 2.89) p=0.007; ﬁgure 5B).
TVR calculations were in line with those of TLR, con-
ﬁrming a similar high efﬁcacy of EES, SES and ZES-R
but not ZES-E or PES at both short-term and long-term
follow-up (see online supplementary ﬁgure S4A,B).
Major adverse cardiac events
The analysis of composite end point of MACE included
31 studies at short-term and 13 at long-term follow-up.
EES and ZES-R were found to be signiﬁcantly superior
to PES (OR 0.63 (95% CI 0.52 to 0.76) p<0.00001 and
OR 0.44 (95% CI 0.21 to 0.92) p=0.03) and ZES-E per-
formed signiﬁcantly worse than SES (OR 1.41 (95% CI
1.13 to 1.76) p=0.002) in reducing the odds of MACE
at ≤1 year (ﬁgure 6A). Long-term follow-up conﬁrmed
the direction and magnitude of the estimates with
EES reducing the odds of MACE by 37% compared
with PES (OR 0.63 (95% CI 0.54 to 0.73) p<0.00001;
ﬁgure 6B)
Sensitivity analyses
Prespeciﬁed sensitivity analyses after exclusion of studies
which did not mandate 12-month DAPT for the out-
comes of MI and ST did not change the magnitude or
direction of the estimates.
Myocardial infarction
Twenty-one studies were included in MI analysis in the
short term. EES signiﬁcantly reduced the odds of MI
compared with PES: OR 0.55 (95% CI 0.40 to 0.76)
p=0.0003. In the overall class comparison, second-
generation DES were associated with a 23% reduction of
odds of MI OR 0.77 (95% CI 0.65 to 0.91) p=0.002 in the
short term. A borderline signiﬁcant class effect favouring
Figure 4 Analysis of definite ST at short-term (A) and long-term (B) follow-up. ORs and 95% CIs. Size of squares is
proportional to the statistical weight of each trial. ST, stent thrombosis.
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second-generation DES was sustained in the long-term
analysis: OR 0.75 (95% CI 0.55 to 1.01) p=0.06, with odds
of MI roughly halved in comparison with EES versus PES:
OR 0.56 (95% CI 0.42 to 0.74) p<0.0001.
Stent thrombosis
For the analysis of deﬁnite ST, 17 studies were included.
In the short term, EES was associated with a signiﬁcant
reduction of odds of ST compared with PES and SES:
OR 0.24 (95% CI 0.12 to 0.50) p=0.0001 and OR 0.46
(95% CI 0.21 to 0.99) p=0.05, respectively.
Second-generation ZES-E increased the odds of ST by
122% compared with ﬁrst-generation SES: OR 2.10
(95% CI 1.06 to 4.16) p=0.03. Results in the long term
conﬁrmed the short-term follow-up ﬁndings; EES was
associated with a more pronounced and signiﬁcant
reduction of odds of ST over time as compared with PES
and SES: OR 0.20 (95% CI 0.08 to 0.49) p=0.0004 and
OR 0.30 (95% CI 0.12 to 0.75) p=0.01, respectively.
DISCUSSION
The present study is the largest report so far comparing
ﬁrst-generation versus second-generation DES. With
31 379 patients included, it provides the most compre-
hensive overview on the safety and efﬁcacy outcomes of
different ﬁrst-generation and second-generation stents.
The main ﬁndings of this meta-analysis are as follows:
(1) second-generation EES and ZES signiﬁcantly
reduced the incidence of MI compared with ﬁrst-
generation PES; (2) only second-generation EES signiﬁ-
cantly reduced the odds of deﬁnite and deﬁnite/prob-
able ST compared with ﬁrst-generation DES (3)
second-generation EES and ZES-R, and the ﬁrst-
generation SES, are similar to each other with regard to
their efﬁcacy and signiﬁcantly better than ZES-E and
PES with regard to repeat coronary revascularisations.
In the present large-scale study analysis, single
and composite safety end points did not differ in direc-
tion or magnitude of the effect favouring durable
polymer EES.
Safety
First-generation DES have been found to be superior to
BMS in reducing restenosis and the need for repeat revas-
cularisation. Their performance in terms of safety, and
strictly, increased propensity for late and very late throm-
botic events, however, was questioned as long follow-up
data were becoming available; further studies showed that
late and very late stent thrombosis could be attributed to
numerous complex mechanisms with device design-
related factors being of paramount importance.4 The
inﬂammation induced by the durable polymers of ﬁrst-
generation DES may result in delayed healing and incom-
plete covering of stent struts by new and functional endo-
thelium, with uncovered stent struts serving as a source
Figure 4 Continued
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for future episodes of ST; second, other factors such as
stent malapposition, mechanical tissue injury caused by
stent struts during implantation and ﬁnally, polymer
hypersensitivity or even toxicity, as is the case for PES,58
in turn associated with persistent ﬁbrin deposition, might
also play a potential role. Second-generation DES were
introduced to address the concerns raised by ﬁrst gener-
ation DES by either optimising their metallic stent
platform or polymer and eluted drug; that is, second-
generation EES uses thin struts coated with durable,
ﬂuorinated polymer, which has been shown to have
thromboresistant properties in experimental studies;
similarly, ZES-R combined more rapid elution kinetics
than sirolimus (SES) in the same time offering thinner,
more biocompatible phosphorylcholine polymer placed
on a cobalt alloy stent platform.7
Figure 5 Analysis of TLR at short-term (A) and long-term (B) follow-up. ORs and 95% CIs. Size of squares is proportional to
the statistical weight of each trial. TLR, target lesion revascularisation.
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In the present meta-analysis, which compared most
robust evidence of ﬁrst-generation versus second-
generation DES data, second-generation EES was found
to be superior in regard to safety end points as com-
pared with ﬁrst-generation PES but not SES; this might
be attributed to the proven overdose and/or accumula-
tion of paclitaxel in the arterial wall due to a coronary
uptake, in turn leading to toxicity, inﬂammation and
late in-stent stenosis, which is not the case with SES.59
The superiority of thin strut EES and ZES in reducing
the incidence of MI in the short clinical follow-up might
also come from mechanistic reasons; indeed, this might
be related to the more frequent side branch jailing with
thick strut devices (SES Cypher 140 µm and PES Taxus
Express 134 µ vs ZES Endeavor/Resolute 91 µm and
Abbott Xience V 81 µm), resulting in turn in higher
rates of periprocedural MI.60–62 Although ST should be
considered a surrogate safety end point, which must be
interpreted in perspective of MI and mortality, it
remains a devastating complication and is often asso-
ciated with high rates of mortality and morbidity.
Second-generation EES was associated with signiﬁcantly
lower rates of deﬁnite and deﬁnite or probable ST in
short-term analysis compared with ﬁrst-generation DES;
this ﬁnding is in line with a meta-analysis by Palmerini,5
which for the ﬁrst time demonstrated the superiority of
EES over BMS and ﬁrst-generation and second-
generation DES in reducing early (0–30 days) and late
(31 days–12 months) ST. This analysis integrates the
most updated data and enriches the previous ﬁndings of
longer follow-up clinical data for particular devices,
demonstrating for the ﬁrst time that EES reduces deﬁn-
ite and deﬁnite or probable ST also beyond these time
frames (very late ST) compared with ﬁrst-generation
DES. Notably, data on EES do not reﬂect the perform-
ance of second-generation ZES-E in terms of stent
thrombosis; indeed, Endeavor was found to even
increase the incidence of deﬁnite ST as compared with
SES at ≤1 year, mainly driven by the results of the SORT
OUT III42 and ZEST55 trials. As zotarolimus is a syn-
thetic analogue of sirolimus, the disparities between
stents are attributed to different kinetics of drug release
from the polymers used for drug elution (1 week
with ZES and 3 months with SES); postulated quick
zotarolimus release and high initial concentrations not
only affect the healing of the plaque and arterial wall,
but may also allow for exposure of the atheromatous
debris to the bloodstream, thus increasing the risk of
early ST, which is of particular importance in high-risk
patients with acute coronary syndrome or multivessel
disease.
Efficacy and MACE
Design-related factors such as strut thickness, type of anti-
proliferative agent, drug elution kinetics, elution time
and type of polymer are all factors that may as well impact
Figure 5 Continued
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efﬁcacy outcomes63; although not a new ﬁnding, in this
analysis all limus-eluting DES, with the exception of
ZES-E, were associated with signiﬁcantly lower rates of
TLR/TVR than the ﬁrst-generation PES. Taken together,
inﬂammation causing properties of paclitaxel along with
the short release curve of ZES-E preclude optimal sup-
pression of procedure related injury responses, in turn
resulting in subsequent intimal hyperplasia and increased
need for repeat revascularisation.64 Unlike ZES-E, the
more recently introduced ZES-R, which has a much
longer (up to 180 days) release curve of the same antipro-
liferative agent, zotarolimus, is associated with a signiﬁ-
cant reduction in TVR/TLR compared with ZES-E.65
In the present paper, we additionally analysed the inci-
dence of MACE, which to the best of our knowledge is
the most proper measure of device performance, as it
Figure 6 Analysis of MACE at short-term (A) and long-term (B) follow-up. ORs and 95% CIs. Size of squares is proportional to
the statistical weight of each trial. MACE, major adverse cardiovascular events.
14 Navarese EP, Kowalewski M, Kandzari D, et al. Open Heart 2014;1:e000064. doi:10.1136/openhrt-2014-000064
Open Heart
group.bmj.com on February 27, 2015 - Published by http://openheart.bmj.com/Downloaded from 
takes into account both safety and efﬁcacy outcomes,
providing statistical power given the low numbers of
single outcome events. Not surprisingly, MACE analysis
conﬁrmed the single-outcome ﬁndings, with second-
generation EES outperforming ﬁrst-generation PES at
≤1 year and beyond. Remarkably, the initial short-term
beneﬁt of SES over ZES-E, attributable mainly to higher
rates of repeat revascularisation with the latter, becomes
less pronounced at long-term follow-up when drug
elution is over.
Limitations
As with any meta-analysis, our study shares the limita-
tions of the original studies. Results were analysed on
trial level data, and therefore we could not assess
whether all baseline characteristics were balanced
among groups (although for the most part they were
balanced within each RCT). Data for follow-ups
longer than 1 year are limited but appear to conﬁrm
the direction of the estimates at ≤1-year. The patient
inclusion criteria of this meta-analysis are broad, more
closely reﬂecting current practice, comprising stable
and unstable high-risk patients. Potentially heteroge-
neous deﬁnitions of MI used across the trials may rep-
resent another limitation.
Another aspect is the duration of dual antiplatelet
therapy (DAPT), that is, the combination of aspirin and
a P2Y12 receptor blocker, which varied among the differ-
ent trials. The variability of DAPT may, however, be less
important in the context of the present meta-analysis
given that BMS were excluded and most trials employed
at least 6 months DAPT duration. Owing to the limited
number of trials comparing ZES-R to ﬁrst-generation
DES, the ﬁndings with this device should be viewed as
exploratory but certainly deserve further attention.
Despite these limitations, this meta-analysis provides the
largest-scale comparative information on the efﬁcacy
and safety proﬁles of different DES in current clinical
practice.
CONCLUSIONS
Second-generation EES and ZES-R offer a similar level
of efﬁcacy compared with ﬁrst-generation SES, but are
more effective than PES; however, only second-
generation EES signiﬁcantly reduced the incidence of
both MI and ST and therefore should be perceived as
the safest DES to date.
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